generally agreed that the bronchodilation obpulmonary disease tained is largely a reflection of the dose of In this paper the term "chronic obstructive bronchodilator administered rather than the pulmonary disease" (COPD) is used as defined mode of administration.
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Definition of chronic obstructive
generally agreed that the bronchodilation obpulmonary disease tained is largely a reflection of the dose of In this paper the term "chronic obstructive bronchodilator administered rather than the pulmonary disease" (COPD) is used as defined mode of administration. 9 It is therefore unlikely in the forthcoming British Thoracic Society that treatment with either a nebuliser or a guidelines for the management of COPD metered dose inhaler will give superior results (1997) as a chronic slowly progressive disorder for most patients provided similar doses are characterised by airways obstruction (reduced given to the lungs by each device. The question forced expiratory volume in one second (FEV 1 ) therefore becomes one of convenience and cost. and ratio of FEV 1 to forced vital capacity For low dose bronchodilator therapy -for ex-(FVC)) which does not change markedly over ample, 100-400 g salbutamol or terbutalineseveral months. Most of the lung function im-treatment with a metered dose inhaler is more pairment is fixed, althugh some reversibility convenient whilst a nebuliser can deliver higher can be produced by bronchodilator (or other) doses more easily. A nebuliser has the further therapy.
advantage of being independent of effort or The guidelines indicate that, in practice, a breathing pattern when a patient is distressed. diagnosis of COPD requires a history of chronic This means that a patient can begin nebulised progressive symptoms such as cough, wheeze treatment using a mask or a mouthpiece while and/or breathlessness without intervening the medical attendent can continue with other periods of "wellness", usually a cigarette smok-tasks. The use of a metered dose inhaler in this ing history of more than 20 pack years, and situation would require the medical attendant objective evidence of airways obstruction (or respiratory therapist or nurse) to stand by (ideally verified by spirometric testing) that the patient and supervise or administer multiple does not return entirely to normal with treat-doses of treatment, possibly more than 20, at ment. one minute intervals. Breathless patients are less likely to be able to inspire slowly or breath hold for optimum lung deposition from a metered dose inhaler.
Acute exacerbations of COPD
The optimum dose of bronchodilator treatCurrent clinical practice is based largely on ment ( agonist or anticholinergic) in acute tradition rather than on careful clinical trials.
COPD is not known. Mestitz et al showed Although patients with COPD are considered that terbutaline was equally effective given by to have relatively static lung function, most metered dose inhaler or nebuliser and the dose have some reversibility and peak flow will often response was still rising at 40 mg. 9 However, show a modest rise during the first few days in doses of agonist above 5-10 mg tend to be hospital. For example, Rebuck et al found that, associated with unacceptable side effects such in 51 patients with COPD, the mean peak flow as tremor or palpitations. Gross and colleagues increased from 70 l/min to 95 l/min (36% rise)
showed that the optimum response to ipra-90 minutes after treatment with a nebulised tropium bromide occurred at 0.4-0.6 mg. 10 A bronchodilator, 1 and a later study reported a review of practice in Britain shows that salrise of 19% in mean peak flow from 113 l/min butamol or terbutaline (5 mg), with or without to 134 l/min in 47 patients with COPD after ipratropium bromide (0.25-0.5 mg), is usually nebulised bronchodilator treatment.
2 These administered to patients with acute airflow obstudies demonstrate that patients with acute struction. 11 This would require 50 inhalations exacerbations of COPD can respond to high of salbutamol followed by 25 inhalations of doses of bronchodilator drugs.
ipratropium bromide via a metered dose inSeveral studies have suggested that patients haler. Most doctors mix salbutamol and iprawith acute asthma or COPD may respond tropium bromide respirator solutions in a single better to treatment with a agonist given by nebuliser chamber and administer it imnebuliser than by metered dose inhaler.
3-5 Howmediately. 11 It has recently been suggested that ever, other authors have suggested that treatthe Turbohaler dry powder device may be used ment with a metered dose inhaler (given effectively by patients with severe airflow through a spacer device) may be as effective as obstruction. 12 13 This would allow the adnebulised treatment in the acute situation. with a nebuliser. different and most studies have contained rel-the airways and nebulised terbutaline or saline benefit. 21 However, the maximum bronchodilator response to agonists and antimay help patients with bronchiectasis to expectorate.
14 Whether this is also true in acute cholinergic agents may not occur until very high doses are reached (more than 20 puffs of COPD is not known.
Does the addition of an anticholinergic agent terbutaline or ipratropium bromide 9 10 ). With these doses it is more convenient (and less to a high dose agonist have any benefit in the treatment of acute exacerbations of COPD? expensive) to deliver the medication by small volume nebuliser. Although combined treatment seems to be more effective in acute asthma, 1 2 the same Other patients may benefit from the physical properties of nebulised treatment. Nebulised authors found that patients with acute exacerbations of COPD did not seem to gain terbutaline aids sputum clearance in patients with bronchiectasis. 14 Differing particle size and any extra benefit from combined treatment. Furthermore, a recent study of 70 patients particle distribution in the airways may produce different responses to treatment with nebulisers admitted to hospital with acute COPD who were not already taking combination nebuliser and metered dose inhalers in some patients even if the same dose is given. In one study a treatment at home failed to show that the addition of nebulised anticholinergic treatment group of patients with COPD had a higher peak flow and subjective response to nebulised during their stay in hospital had a clear beneficial effect on symptoms, spirometric para-drugs than to the same drugs given by metered dose inhaler and spacer. 18 However, other meters, or length of stay. 15 These results were unexpected as combination treatment produces patients had a higher subjective and objective response to the lower dose of treatment given increased bronchodilatation in patients with stable bronchitis. 16 17 Furthermore, patients by metered dose inhaler and spacer. 18 These differences may be due to the different diswith severe but stable COPD who took part in a home nebuliser trial had slightly (but not tribution of particles in the airways between patients. The dose of inhaled drug available significantly) higher mean daily peak flow rates using combined salbutamol and ipratropium for systemic absorption also differs between a metered dose inhaler and a nebuliser and this bromide than using either agent alone. 18 The exact role of ipratropium bromide in acute could could increase or decrease the systemic effects for the same dose. exacerbations of COPD therefore remains incompletely defined and further studies are required.
The optimum duration of nebuliser treat-         ment is not known. Based on clinical practice and experience, it is suggested that nebulised Given the differing requirements (and inhaler skills) of different patients, and the variable salbutamol (2.5-5 mg) or terbutaline (5-10 mg) be given 4-6 hourly for 24-48 hours or performance characteristics of different inhaler and nebuliser devices, it is hardly surprising until the patient is clinically stable. Ipratropium bromide (0.5 mg) should be added if the patient that clinical trials of home nebulisers in COPD have yielded conflicting results. Some studies is known to benefit from it or if there is a poor response to agonist therapy. The patient have shown that nebulisers were superior to metered dose inhalers based on improvements should be changed to a metered dose inhaler 24-48 hours before discharge to ensure that the in spirometric values and symptoms. 18 22 23 In other studies nebulisers and metered dose inpatient is stable, to check the inhaler technique, and to reassure the patient that his or her halers were found to be equally effective. 9 24 25 Some of the differences in these studies can be condition is controlled by their usual medication. explained by differences in patient groups and doses and devices. For example, Jenkins et al 25 excluded patients who did not have a satisfactory response to conventional metered dose inhaler treatment, whereas these are presumably the patients who are most likely to Home nebuliser use for patients with COPD benefit from high dose nebuliser treatment.
There are also methodological problems with This remains a controversial area and the arguments for and against home nebuliser treat-home nebuliser trials as there is no perfect placebo for a nebulised treatment (nebulised ment have been well reviewed. 19 20 Home nebulisers have been widely used in the past saline might alter airway calibre or mucus clearance). Morrison et al 23 compared nebulised for patients who were unable to use metered dose inhalers. With the advent of spacer de-saline with nebulised ipratropium bromide and fenoterol in a double blind, randomised, vices, self activated inhalers, dry powder inhalers, and other inhalation devices this is no placebo controlled study. The mean daily peak flow (PEF) rose by 19% (from 164 to 196 l/ longer a valid reason for prescribing a home nebuliser except in a very few cases. 19 20 Home min) on the active nebuliser treatment compared with nebulised saline supplemented by nebulisers may benefit some patients with COPD who require large doses of inhaled med-"rescue" metered dose inhaler bronchodilator therapy. This impressive rise in PEF was almost ication. Most patients derive optimum benefit from standard doses of bronchodilators ad-identical to that observed by O'Driscoll et al. 18 These studies suggest that there is, indeed, a ministered by metered dose inhaler and, for these patients, giving increasing doses of med-small population of patients with severe COPD who derive greater subjective and objective ication produces little subjective or objective group.bmj.com on October 29, 2017 -Published by http://thorax.bmj.com/ Downloaded from benefit from a high dose nebulised broncho-precaution when the first dose of nebulised bronchodilator is given to a patient with known dilator than from lower dose metered dose inhaler treatment.
ischaemic heart disease or cardiac arrhythmias. Perhaps the greatest danger is over reliance by patients on home nebulisers rather than the summoning of medical help in an emergency.   Details of home nebuliser assessment for The frequency with which this happens is not known. Other theoretical hazards include the patients with COPD are given in the guidelines on page S10. The key steps are: development of tachyphylaxis during prolonged administration, although there is no 1. An assessment by a respiratory specialist to confirm the diagnosis of COPD and to explore evidence for this in clinical practice, 31 and the risk (which largely applies to hospitalised other treatment options. An assessment needs to be made also of a patient's ability to use patients with acute COPD) of giving prolonged nebulised treatment driven by pure oxygen to hand held inhalers. 2. A recording of baseline home peak flow patients who have type II respiratory failure thus worsening carbon dioxide retention. Caretaken twice daily on the patient's usual inhaled treatment.
ful attention to limiting the duration of nebulisation and the use of air driven nebulisers 3. A trial of treatment with an oral steroid, if not already done.
in selected patients should avoid this hazard, which in practice is rarely a significant problem. 4. A trial of high dose treatment by hand held inhaler -for example, a dry powder device or
The life expectancy of patients with severe COPD is mainly determined by the severity of metered dose inhaler and spacer with 1 mg terbutaline or 400 g salbutamol and 160 g their air flow obstruction. 32 A recent study has shown that the five year survival of patients ipratropium bromide four times daily. 5. A formal trial of a home nebuliser -for using nebulisers and metered dose inhalers was similar. 33 These patients had similar FEV 1 example, 2.5-5 mg salbutamol or 5-10 mg terbutaline four times daily or ipratropium brom-values on entry to the study (0.88 l) and the five year mortality was approximately 46%, ide 0.25-0.5 mg four times daily or a combination of these treatments. most deaths being due to respiratory failure or lung cancer with the risk of death being directly 6. A careful assessment of the patient's response to these treatments over at least two related to the patient's initial FEV 1 . These data provide some reassurance as they suggest that weeks each. Laboratory based single dose reversibility studies will not identify patients who the excess mortality amongst nebuliser users in cross sectional studies is probably due to disease should be given home nebuliser therapy and such trials cannot identify the best treatment severity rather than the treatment.
If ipratropium bromide is used, patients with options for individual patients. 26 27 7. After an assessment process the clinician prostatism should use the smallest possible dose to reduce the risk of acute urinary retention must decide with the patient if the nebuliser treatment has produced subjective and ob-and patients with a history of glaucoma should use a mouthpiece rather than a face mask. If a jective benefit. The doctor and patient need to discuss whether the degree of benefit is suffi-face mask must be used every care should be taken to keep the droplets of medication away cient to justify the high cost and inconvenience of home nebuliser therapy.
from the eyes. For example, the mask should be closely fitted to the nose and side vent holes should be taped over using adhesive tape.     
